Kane Biotech, a Canadian biotechnology company that develops products that prevent and disperse microbial biofilms, has been granted U.S. Patent No. 7,556,807, "Signal peptides, nucleic acid molecules and methods for treatment of caries." This is the company's second patent relating to its competence stimulating peptide (CSP) technology, according to Kane.
The new patent discloses and claims a method of inhibiting dental plaque and treating plaque-associated conditions, such as dental caries and periodontal disease, using analogues of CSP peptide in oral care formulations, the company said. Dennis Cvitkovitch, Ph.D., of the Dental Research Institute at the University of Toronto, discoverer of CSP in Streptococcus mutans, has demonstrated the ability of CSP analogue peptides to inhibit streptococcal biofilm (dental plaque) formation.
"This quorum-sensing peptide technology provides a novel target for developing oral care products using CSP analogues that competitively inhibit CSP-mediated pathway and therefore hinder the formation of dental plaque," said Sri Madhyastha, Ph.D., vice president of research and chief scientific officer of Kane, in a press release. "This oral prophylactic strategy specifically disarms virulent target bacteria, while leaving beneficial bacteria unharmed during therapy, with a side benefit of minimizing the chances of bacteria developing resistance."
Copyright © 2009 DrBicuspid.com
